Register entry
ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC
- Registered sites
- 0
- Active NDC listings
- 0
- Live patents
- 27
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
27| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 7417042*PED | KYPROLIScarfilzomib | use | Jan 2027 |
| 7737112 | KYPROLIScarfilzomib | product | Dec 2027 |
| 7737112*PED | KYPROLIScarfilzomib | use | Jun 2028 |
| RE47954 | KYPROLIScarfilzomib | use | Oct 2029 |
| RE47954*PED | KYPROLIScarfilzomib | use | Apr 2030 |
| 9493582 | KYPROLIScarfilzomib | product | Feb 2033 |
| 9493582*PED | KYPROLIScarfilzomib | use | Aug 2033 |
| 12636340 | KYPROLIScarfilzomib | use | Apr 2041 |
| 12636340*PED | KYPROLIScarfilzomib | use | Oct 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| KYPROLISCARFILZOMIB | PED Paediatric | Nov 2028 |
Enquiry
Common questions
- Is ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC FDA approved?
- ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC holds no registered establishment of its own; it appears here on its Orange Book patents.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.